Welcome to our dedicated page for Prelude Therapeutics Incorporated news (Ticker: PRLD), a resource for investors and traders seeking the latest updates and insights on Prelude Therapeutics Incorporated stock.
Prelude Therapeutics Incorporated (Nasdaq: PRLD) is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies targeting key mechanisms in cancers with high unmet needs. Founded in 2016 and headquartered in Wilmington, Delaware, the company's mission is to deliver precision oncology treatments that can address the critical pathways in cancer cells.
Prelude's robust pipeline includes several promising drug candidates currently in clinical development:
- PRT543: This candidate is in Phase 1 clinical trials targeting select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies.
- PRT811: Also in Phase 1 trials, PRT811 focuses on solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas.
- PRT1419: A potent and selective inhibitor of the anti-apoptotic protein MCL1, which is undergoing clinical evaluation for its efficacy and safety in cancer treatment.
- PRT2527: This highly selective CDK9 inhibitor demonstrates substantial potential in treating solid and hematological malignancies and aims to minimize off-target toxicities.
- PRT3645: A next-generation CDK4/6 inhibitor that shows promise for better safety, tolerability, and efficacy in various cancers beyond breast cancer.
- PRT3789: A first-in-class SMARCA2 protein degrader targeting cancers with SMARCA4 mutations.
In recent developments, Prelude has extended its cash runway into 2026 following a successful public offering, raising approximately $113 million in gross proceeds. Their strategic collaboration with AbCellera aims to co-develop innovative antibody drug conjugate therapies, combining AbCellera's antibody discovery platform with Prelude's expertise in medicinal chemistry and drug development.
Prelude's financial strength is evident with cash, cash equivalents, and marketable securities totaling $255 million as of June 30, 2023. Their focused approach on advancing their pipeline and making critical strategic decisions is supported by clinical data showing promising efficacy and safety profiles for their drug candidates, such as PRT2527 and PRT1419. The company's commitment to addressing cancers with high unmet needs positions it as a significant player in precision oncology.
For more detailed information and the latest updates on Prelude Therapeutics' research advancements, financial performance, and strategic initiatives, visit their official website and follow them on LinkedIn and Twitter.
Prelude Therapeutics, a clinical-stage precision oncology company (Nasdaq: PRLD), announced participation in three healthcare investment conferences. On May 2, CEO Kris Vaddi will engage in a fireside chat at the H. C. Wainwright BioConnect Investor Conference at Nasdaq. The Bank of America Securities 2023 Healthcare Conference will feature Dr. Jane Huang and CFO Laurent Chardonnet in one-on-one meetings on May 10 and 11, with Dr. Huang presenting a fireside chat on May 10 at 4:20 p.m. PT. Lastly, during the JMP Securities Life Sciences Conference on May 15 and 16, Dr. Vaddi and Mr. Chardonnet will hold one-on-one meetings, with Dr. Vaddi participating in a fireside chat on May 15 at noon ET. Prelude's pipeline includes four promising drug candidates targeting key cancer pathways.
Prelude Therapeutics (Nasdaq: PRLD), a clinical-stage precision oncology company, announced the presentation of eight abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2023, occurring from April 14-19 in Orlando, Florida. The research highlights progress in their pipeline, including two clinical abstracts on compounds PRT1419 and PRT2527, which target specific cancer pathways in advanced tumors. Jane Huang, President and CMO, noted the supportive safety and pharmacokinetic profiles for further development in hematological cancers. Additionally, preclinical data on the SMARCA2 degrader program will be presented, alongside favorable data on other candidates such as PRT3645 and PRT3789. This showcases Prelude's commitment to innovative treatment options for cancer patients.
Prelude Therapeutics (Nasdaq: PRLD) reported significant advancements in its clinical pipeline during 2022, highlighting four differentiated compounds in Phase 1 trials. The company aims to present initial data from its PRT2527 and PRT1419 programs at the upcoming AACR Annual Meeting. As of December 31, 2022, Prelude's cash reserves stood at $201.7 million, sufficient to fund operations through Q4 2024. Research and development expenses increased to $92.9 million, while general and administrative costs rose to $30.7 million. The company posted a net loss of $115.4 million for the fiscal year, slightly higher than the previous year.
Prelude Therapeutics (Nasdaq: PRLD) announced a clinical trial collaboration with BeiGene to evaluate its CDK9 inhibitor, PRT2527, alongside BeiGene's BTK inhibitor, zanubrutinib, for treating hematologic malignancies. This collaboration is based on recent evidence showing enhanced efficacy of CDK9 and BTK inhibition in B cell malignancies.
Prelude retains all operational and commercial rights for PRT2527 while BeiGene provides zanubrutinib. PRT2527 is currently undergoing a Phase 1 dose-escalation study for advanced solid tumors and hematologic malignancies, demonstrating potential as a selective and potent treatment option.
Prelude Therapeutics, a clinical-stage precision oncology company, announced its participation in the Barclays Global Healthcare Conference in Miami from March 14 to 16, 2023. On March 16 at 9:30 a.m. ET, CEO Kris Vaddi and CMO Jane Huang will engage in a fireside chat. One-on-one meetings are scheduled for March 15 and 16.
Prelude focuses on developing innovative drug candidates targeting critical cancer pathways, with a pipeline featuring four candidates: PRT1419, PRT2527, PRT3645, and PRT3789.
FAQ
What is the current stock price of Prelude Therapeutics Incorporated (PRLD)?
What is the market cap of Prelude Therapeutics Incorporated (PRLD)?
What does Prelude Therapeutics Incorporated specialize in?
Where is Prelude Therapeutics Incorporated based?
What are some key drug candidates in Prelude Therapeutics' pipeline?
What is PRT2527?
What recent financial achievement has Prelude Therapeutics reported?
Who has Prelude Therapeutics partnered with for drug development?
What is PRT3645?
What is the focus of PRT3789?
What are the financial resources available to Prelude Therapeutics?
Where can I find more information about Prelude Therapeutics?
